PUMA BIOTECHNOLOGY INC (PBYI) Fundamental Analysis & Valuation

NASDAQ:PBYI • US74587V1070

Current stock price

6.9 USD
+0.14 (+2.07%)
At close:
6.88 USD
-0.02 (-0.29%)
After Hours:

This PBYI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. PBYI Profitability Analysis

1.1 Basic Checks

  • PBYI had positive earnings in the past year.
  • In the past year PBYI had a positive cash flow from operations.
  • In multiple years PBYI reported negative net income over the last 5 years.
  • Of the past 5 years PBYI 4 years had a positive operating cash flow.
PBYI Yearly Net Income VS EBIT VS OCF VS FCFPBYI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • PBYI has a Return On Assets of 14.38%. This is amongst the best in the industry. PBYI outperforms 94.97% of its industry peers.
  • PBYI has a Return On Equity of 23.87%. This is amongst the best in the industry. PBYI outperforms 96.33% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 24.01%, PBYI belongs to the top of the industry, outperforming 98.07% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for PBYI is below the industry average of 27.17%.
  • The 3 year average ROIC (23.01%) for PBYI is below the current ROIC(24.01%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 14.38%
ROE 23.87%
ROIC 24.01%
ROA(3y)12.65%
ROA(5y)5.02%
ROE(3y)32.38%
ROE(5y)N/A
ROIC(3y)23.01%
ROIC(5y)16.86%
PBYI Yearly ROA, ROE, ROICPBYI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

  • PBYI's Profit Margin of 13.62% is amongst the best of the industry. PBYI outperforms 92.26% of its industry peers.
  • With an excellent Operating Margin value of 16.33%, PBYI belongs to the best of the industry, outperforming 92.46% of the companies in the same industry.
  • PBYI's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 74.53%, PBYI belongs to the top of the industry, outperforming 82.59% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PBYI has declined.
Industry RankSector Rank
OM 16.33%
PM (TTM) 13.62%
GM 74.53%
OM growth 3Y16.09%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.57%
GM growth 5Y-2.01%
PBYI Yearly Profit, Operating, Gross MarginsPBYI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PBYI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PBYI is creating value.
  • The number of shares outstanding for PBYI has been increased compared to 1 year ago.
  • Compared to 5 years ago, PBYI has more shares outstanding
  • Compared to 1 year ago, PBYI has an improved debt to assets ratio.
PBYI Yearly Shares OutstandingPBYI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PBYI Yearly Total Debt VS Total AssetsPBYI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • PBYI has an Altman-Z score of -3.78. This is a bad value and indicates that PBYI is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -3.78, PBYI perfoms like the industry average, outperforming 42.94% of the companies in the same industry.
  • There is no outstanding debt for PBYI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.54
Altman-Z -3.78
ROIC/WACC2.42
WACC9.93%
PBYI Yearly LT Debt VS Equity VS FCFPBYI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

2.3 Liquidity

  • A Current Ratio of 2.00 indicates that PBYI has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.00, PBYI is not doing good in the industry: 76.79% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.93 indicates that PBYI should not have too much problems paying its short term obligations.
  • PBYI has a Quick ratio of 1.93. This is in the lower half of the industry: PBYI underperforms 76.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.93
PBYI Yearly Current Assets VS Current LiabilitesPBYI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PBYI Growth Analysis

3.1 Past

  • The earnings per share for PBYI have decreased by 0.00% in the last year.
  • The Revenue has decreased by -0.91% in the past year.
  • The Revenue has been growing slightly by 0.29% on average over the past years.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y0.05%
Revenue growth 5Y0.29%
Sales Q2Q%27.75%

3.2 Future

  • PBYI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.16% yearly.
  • Based on estimates for the next years, PBYI will show a decrease in Revenue. The Revenue will decrease by -0.50% on average per year.
EPS Next Y-58.2%
EPS Next 2Y-8.56%
EPS Next 3Y-9.04%
EPS Next 5Y-10.16%
Revenue Next Year-1.58%
Revenue Next 2Y-0.79%
Revenue Next 3Y-0.53%
Revenue Next 5Y-0.5%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PBYI Yearly Revenue VS EstimatesPBYI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
PBYI Yearly EPS VS EstimatesPBYI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

6

4. PBYI Valuation Analysis

4.1 Price/Earnings Ratio

  • PBYI is valuated reasonably with a Price/Earnings ratio of 11.31.
  • Based on the Price/Earnings ratio, PBYI is valued cheaper than 96.52% of the companies in the same industry.
  • PBYI's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.60.
  • The Price/Forward Earnings ratio is 27.06, which means the current valuation is very expensive for PBYI.
  • 92.84% of the companies in the same industry are more expensive than PBYI, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 22.84. PBYI is around the same levels.
Industry RankSector Rank
PE 11.31
Fwd PE 27.06
PBYI Price Earnings VS Forward Price EarningsPBYI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBYI indicates a rather cheap valuation: PBYI is cheaper than 98.26% of the companies listed in the same industry.
  • PBYI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PBYI is cheaper than 97.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.41
EV/EBITDA 4.32
PBYI Per share dataPBYI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • PBYI has a very decent profitability rating, which may justify a higher PE ratio.
  • PBYI's earnings are expected to decrease with -9.04% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.56%
EPS Next 3Y-9.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PBYI Dividend Analysis

5.1 Amount

  • No dividends for PBYI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PBYI Fundamentals: All Metrics, Ratios and Statistics

PUMA BIOTECHNOLOGY INC

NASDAQ:PBYI (4/2/2026, 8:00:02 PM)

After market: 6.88 -0.02 (-0.29%)

6.9

+0.14 (+2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners72.67%
Inst Owner Change4.1%
Ins Owners15.37%
Ins Owner Change2.47%
Market Cap351.07M
Revenue(TTM)228.37M
Net Income(TTM)31.11M
Analysts43.33
Price Target5.1 (-26.09%)
Short Float %9.56%
Short Ratio9.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)141.33%
Min EPS beat(2)12.29%
Max EPS beat(2)270.37%
EPS beat(4)4
Avg EPS beat(4)172.84%
Min EPS beat(4)12.29%
Max EPS beat(4)394.12%
EPS beat(8)8
Avg EPS beat(8)133.14%
EPS beat(12)11
Avg EPS beat(12)149.94%
EPS beat(16)14
Avg EPS beat(16)219.83%
Revenue beat(2)2
Avg Revenue beat(2)6.33%
Min Revenue beat(2)4.77%
Max Revenue beat(2)7.9%
Revenue beat(4)4
Avg Revenue beat(4)3.78%
Min Revenue beat(4)1.23%
Max Revenue beat(4)7.9%
Revenue beat(8)8
Avg Revenue beat(8)5.64%
Revenue beat(12)10
Avg Revenue beat(12)3.66%
Revenue beat(16)13
Avg Revenue beat(16)4.88%
PT rev (1m)0%
PT rev (3m)7.14%
EPS NQ rev (1m)-417.07%
EPS NQ rev (3m)-417.07%
EPS NY rev (1m)-37.5%
EPS NY rev (3m)-44.38%
Revenue NQ rev (1m)-14.29%
Revenue NQ rev (3m)-14.29%
Revenue NY rev (1m)-0.91%
Revenue NY rev (3m)-1.13%
Valuation
Industry RankSector Rank
PE 11.31
Fwd PE 27.06
P/S 1.54
P/FCF 8.41
P/OCF 8.4
P/B 2.69
P/tB 3.95
EV/EBITDA 4.32
EPS(TTM)0.61
EY8.84%
EPS(NY)0.26
Fwd EY3.7%
FCF(TTM)0.82
FCFY11.89%
OCF(TTM)0.82
OCFY11.91%
SpS4.49
BVpS2.56
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.93
Profitability
Industry RankSector Rank
ROA 14.38%
ROE 23.87%
ROCE 27.62%
ROIC 24.01%
ROICexc 86.43%
ROICexgc N/A
OM 16.33%
PM (TTM) 13.62%
GM 74.53%
FCFM 18.27%
ROA(3y)12.65%
ROA(5y)5.02%
ROE(3y)32.38%
ROE(5y)N/A
ROIC(3y)23.01%
ROIC(5y)16.86%
ROICexc(3y)111.4%
ROICexc(5y)74%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.47%
ROCE(5y)19.39%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y38.42%
ROICexc growth 5YN/A
OM growth 3Y16.09%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.57%
GM growth 5Y-2.01%
F-Score7
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.54
Debt/EBITDA 0
Cap/Depr 0.65%
Cap/Sales 0.03%
Interest Coverage 6.41
Cash Conversion 86.66%
Profit Quality 134.14%
Current Ratio 2
Quick Ratio 1.93
Altman-Z -3.78
F-Score7
WACC9.93%
ROIC/WACC2.42
Cap/Depr(3y)36.96%
Cap/Depr(5y)37.87%
Cap/Sales(3y)1.81%
Cap/Sales(5y)1.7%
Profit Quality(3y)109.68%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y-58.2%
EPS Next 2Y-8.56%
EPS Next 3Y-9.04%
EPS Next 5Y-10.16%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y0.05%
Revenue growth 5Y0.29%
Sales Q2Q%27.75%
Revenue Next Year-1.58%
Revenue Next 2Y-0.79%
Revenue Next 3Y-0.53%
Revenue Next 5Y-0.5%
EBIT growth 1Y20.45%
EBIT growth 3Y16.16%
EBIT growth 5YN/A
EBIT Next Year9.09%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.41%
OCF growth 3YN/A
OCF growth 5Y122.3%

PUMA BIOTECHNOLOGY INC / PBYI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PUMA BIOTECHNOLOGY INC?

ChartMill assigns a fundamental rating of 5 / 10 to PBYI.


What is the valuation status of PUMA BIOTECHNOLOGY INC (PBYI) stock?

ChartMill assigns a valuation rating of 6 / 10 to PUMA BIOTECHNOLOGY INC (PBYI). This can be considered as Fairly Valued.


How profitable is PUMA BIOTECHNOLOGY INC (PBYI) stock?

PUMA BIOTECHNOLOGY INC (PBYI) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for PBYI stock?

The Price/Earnings (PE) ratio for PUMA BIOTECHNOLOGY INC (PBYI) is 11.31 and the Price/Book (PB) ratio is 2.69.


How financially healthy is PUMA BIOTECHNOLOGY INC?

The financial health rating of PUMA BIOTECHNOLOGY INC (PBYI) is 6 / 10.